The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: Multiple myeloma, lymphoma, and acute leukemia

Michael Boyiadzis, Michael R. Bishop, Rafat Abonour, Kenneth C. Anderson, Stephen M. Ansell, David Avigan, Lisa Barbarotta, Austin John Barrett, Koen Besien, P. Leif Bergsagel, Ivan Borrello, Joshua Brody, Jill Brufsky, Mitchell Cairo, Ajai Chari, Adam Cohen, Jorge Cortes, Stephen J. Forman, Jonathan W. Friedberg, Ephraim J. FuchsSteven D. Gore, Sundar Jagannath, Brad S. Kahl, Justin Kline, James N. Kochenderfer, Larry W. Kwak, Ronald Levy, Marcos Lima, Mark R. Litzow, Anuj Mahindra, Jeffrey Miller, Nikhil C. Munshi, Robert Z. Orlowski, John M. Pagel, David L. Porter, Stephen J. Russell, Karl Schwartz, Margaret A. Shipp, David Siegel, Richard M. Stone, Martin S. Tallman, John M. Timmerman, Frits Rhee, Edmund K. Waller, Ann Welsh, Michael Werner, Peter H. Wiernik, Madhav V. Dhodapkar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine's clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.

Original languageEnglish (US)
Article number90
JournalJournal for ImmunoTherapy of Cancer
Volume4
Issue number1
DOIs
StatePublished - Dec 20 2016

Fingerprint

Hematologic Neoplasms
Multiple Myeloma
Immunotherapy
Lymphoma
Leukemia
Neoplasms
Therapeutics
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division
Politics
Practice Guidelines
Patient Selection
Immune System
Nurses
Guidelines
Physicians

Keywords

  • Acute leukemia
  • Cancer immunotherapy
  • Hematologic malignancies
  • Immunotherapy
  • Lymphoma
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Cancer Research
  • Molecular Medicine
  • Pharmacology
  • Immunology

Cite this

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies : Multiple myeloma, lymphoma, and acute leukemia. / Boyiadzis, Michael; Bishop, Michael R.; Abonour, Rafat; Anderson, Kenneth C.; Ansell, Stephen M.; Avigan, David; Barbarotta, Lisa; Barrett, Austin John; Besien, Koen; Bergsagel, P. Leif; Borrello, Ivan; Brody, Joshua; Brufsky, Jill; Cairo, Mitchell; Chari, Ajai; Cohen, Adam; Cortes, Jorge; Forman, Stephen J.; Friedberg, Jonathan W.; Fuchs, Ephraim J.; Gore, Steven D.; Jagannath, Sundar; Kahl, Brad S.; Kline, Justin; Kochenderfer, James N.; Kwak, Larry W.; Levy, Ronald; Lima, Marcos; Litzow, Mark R.; Mahindra, Anuj; Miller, Jeffrey; Munshi, Nikhil C.; Orlowski, Robert Z.; Pagel, John M.; Porter, David L.; Russell, Stephen J.; Schwartz, Karl; Shipp, Margaret A.; Siegel, David; Stone, Richard M.; Tallman, Martin S.; Timmerman, John M.; Rhee, Frits; Waller, Edmund K.; Welsh, Ann; Werner, Michael; Wiernik, Peter H.; Dhodapkar, Madhav V.

In: Journal for ImmunoTherapy of Cancer, Vol. 4, No. 1, 90, 20.12.2016.

Research output: Contribution to journalArticle

Boyiadzis, M, Bishop, MR, Abonour, R, Anderson, KC, Ansell, SM, Avigan, D, Barbarotta, L, Barrett, AJ, Besien, K, Bergsagel, PL, Borrello, I, Brody, J, Brufsky, J, Cairo, M, Chari, A, Cohen, A, Cortes, J, Forman, SJ, Friedberg, JW, Fuchs, EJ, Gore, SD, Jagannath, S, Kahl, BS, Kline, J, Kochenderfer, JN, Kwak, LW, Levy, R, Lima, M, Litzow, MR, Mahindra, A, Miller, J, Munshi, NC, Orlowski, RZ, Pagel, JM, Porter, DL, Russell, SJ, Schwartz, K, Shipp, MA, Siegel, D, Stone, RM, Tallman, MS, Timmerman, JM, Rhee, F, Waller, EK, Welsh, A, Werner, M, Wiernik, PH & Dhodapkar, MV 2016, 'The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: Multiple myeloma, lymphoma, and acute leukemia', Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, 90. https://doi.org/10.1186/s40425-016-0188-z
Boyiadzis, Michael ; Bishop, Michael R. ; Abonour, Rafat ; Anderson, Kenneth C. ; Ansell, Stephen M. ; Avigan, David ; Barbarotta, Lisa ; Barrett, Austin John ; Besien, Koen ; Bergsagel, P. Leif ; Borrello, Ivan ; Brody, Joshua ; Brufsky, Jill ; Cairo, Mitchell ; Chari, Ajai ; Cohen, Adam ; Cortes, Jorge ; Forman, Stephen J. ; Friedberg, Jonathan W. ; Fuchs, Ephraim J. ; Gore, Steven D. ; Jagannath, Sundar ; Kahl, Brad S. ; Kline, Justin ; Kochenderfer, James N. ; Kwak, Larry W. ; Levy, Ronald ; Lima, Marcos ; Litzow, Mark R. ; Mahindra, Anuj ; Miller, Jeffrey ; Munshi, Nikhil C. ; Orlowski, Robert Z. ; Pagel, John M. ; Porter, David L. ; Russell, Stephen J. ; Schwartz, Karl ; Shipp, Margaret A. ; Siegel, David ; Stone, Richard M. ; Tallman, Martin S. ; Timmerman, John M. ; Rhee, Frits ; Waller, Edmund K. ; Welsh, Ann ; Werner, Michael ; Wiernik, Peter H. ; Dhodapkar, Madhav V. / The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies : Multiple myeloma, lymphoma, and acute leukemia. In: Journal for ImmunoTherapy of Cancer. 2016 ; Vol. 4, No. 1.
@article{6d571f62cb5f41b9bd3ec21b7e0fdbed,
title = "The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: Multiple myeloma, lymphoma, and acute leukemia",
abstract = "Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine's clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.",
keywords = "Acute leukemia, Cancer immunotherapy, Hematologic malignancies, Immunotherapy, Lymphoma, Multiple myeloma",
author = "Michael Boyiadzis and Bishop, {Michael R.} and Rafat Abonour and Anderson, {Kenneth C.} and Ansell, {Stephen M.} and David Avigan and Lisa Barbarotta and Barrett, {Austin John} and Koen Besien and Bergsagel, {P. Leif} and Ivan Borrello and Joshua Brody and Jill Brufsky and Mitchell Cairo and Ajai Chari and Adam Cohen and Jorge Cortes and Forman, {Stephen J.} and Friedberg, {Jonathan W.} and Fuchs, {Ephraim J.} and Gore, {Steven D.} and Sundar Jagannath and Kahl, {Brad S.} and Justin Kline and Kochenderfer, {James N.} and Kwak, {Larry W.} and Ronald Levy and Marcos Lima and Litzow, {Mark R.} and Anuj Mahindra and Jeffrey Miller and Munshi, {Nikhil C.} and Orlowski, {Robert Z.} and Pagel, {John M.} and Porter, {David L.} and Russell, {Stephen J.} and Karl Schwartz and Shipp, {Margaret A.} and David Siegel and Stone, {Richard M.} and Tallman, {Martin S.} and Timmerman, {John M.} and Frits Rhee and Waller, {Edmund K.} and Ann Welsh and Michael Werner and Wiernik, {Peter H.} and Dhodapkar, {Madhav V.}",
year = "2016",
month = "12",
day = "20",
doi = "10.1186/s40425-016-0188-z",
language = "English (US)",
volume = "4",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of hematologic malignancies

T2 - Multiple myeloma, lymphoma, and acute leukemia

AU - Boyiadzis, Michael

AU - Bishop, Michael R.

AU - Abonour, Rafat

AU - Anderson, Kenneth C.

AU - Ansell, Stephen M.

AU - Avigan, David

AU - Barbarotta, Lisa

AU - Barrett, Austin John

AU - Besien, Koen

AU - Bergsagel, P. Leif

AU - Borrello, Ivan

AU - Brody, Joshua

AU - Brufsky, Jill

AU - Cairo, Mitchell

AU - Chari, Ajai

AU - Cohen, Adam

AU - Cortes, Jorge

AU - Forman, Stephen J.

AU - Friedberg, Jonathan W.

AU - Fuchs, Ephraim J.

AU - Gore, Steven D.

AU - Jagannath, Sundar

AU - Kahl, Brad S.

AU - Kline, Justin

AU - Kochenderfer, James N.

AU - Kwak, Larry W.

AU - Levy, Ronald

AU - Lima, Marcos

AU - Litzow, Mark R.

AU - Mahindra, Anuj

AU - Miller, Jeffrey

AU - Munshi, Nikhil C.

AU - Orlowski, Robert Z.

AU - Pagel, John M.

AU - Porter, David L.

AU - Russell, Stephen J.

AU - Schwartz, Karl

AU - Shipp, Margaret A.

AU - Siegel, David

AU - Stone, Richard M.

AU - Tallman, Martin S.

AU - Timmerman, John M.

AU - Rhee, Frits

AU - Waller, Edmund K.

AU - Welsh, Ann

AU - Werner, Michael

AU - Wiernik, Peter H.

AU - Dhodapkar, Madhav V.

PY - 2016/12/20

Y1 - 2016/12/20

N2 - Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine's clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.

AB - Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine's clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.

KW - Acute leukemia

KW - Cancer immunotherapy

KW - Hematologic malignancies

KW - Immunotherapy

KW - Lymphoma

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85006745449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006745449&partnerID=8YFLogxK

U2 - 10.1186/s40425-016-0188-z

DO - 10.1186/s40425-016-0188-z

M3 - Article

AN - SCOPUS:85006745449

VL - 4

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 90

ER -